Mastaplex, the Dunedin-based agricultural technology company, has announced its expansion into South American markets, a move that forms part of a wider strategy to secure distribution agreements across major dairy-producing regions worldwide. The company, which specialises in on-farm diagnostic equipment for livestock health, said the new arrangement would extend its reach into one of the world's largest dairy farming continents.

The firm's core product is a testing device that allows farmers to detect bovine mastitis directly on their farms, without needing to send samples away for laboratory analysis. Mastitis, an inflammation of the udder tissue typically caused by bacterial infection, remains one of the most persistent and costly health problems facing dairy herds globally. It can reduce milk yield, compromise milk quality and, in severe cases, force farmers to cull affected animals. Industry estimates have long placed the economic burden of the disease in the billions of pounds annually across the international dairy sector, arising from lost production, treatment costs and early herd replacement.

By enabling earlier detection, Mastaplex's technology is intended to help farmers intervene before an infection spreads or worsens, reducing both the financial impact and the volume of antibiotics required for treatment. This latter point has taken on added significance in recent years as regulators and consumers alike have pushed for reduced antibiotic use in agriculture.

Mastaplex keeps its entire operation, including its headquarters, research and development division and manufacturing facilities, in Dunedin. The company has resisted moving any part of its production or design work offshore, a decision it attributes to the strength of the scientific talent and infrastructure available in the city.

Chief executive Olaf Bork developed the underlying diagnostic technology and continues to lead the company. The intellectual property behind the testing device originated in research carried out in partnership with the University of Otago, where much of the early scientific work establishing the diagnostic method was conducted. That academic grounding has remained central to the company's identity as it has grown from a research project into a commercial exporter.

Bork has previously described the decision to keep operations in Dunedin as a deliberate one, arguing that proximity to the university's research base and access to a skilled local workforce outweigh any advantages that might come from relocating manufacturing overseas. The company's growth to date has relied on building relationships with distributors in established dairy markets before pursuing newer ones.

The move into South America follows earlier distribution deals in other dairy-producing regions and reflects Mastaplex's stated ambition of building a presence in every major dairy market internationally. Company executives have indicated that further agreements are under discussion in additional territories, though details of those talks have not yet been made public.

For a company of its size, the international expansion represents a considerable undertaking. Entering new markets typically requires navigating different regulatory regimes for veterinary and diagnostic equipment, as well as establishing relationships with local distributors who understand regional farming practices. Mastaplex has not disclosed the value of the South American agreement or named its distribution partners in the region.

The company's leadership has framed the expansion as evidence that a New Zealand-developed technology can compete on the global stage without sacrificing its domestic roots. Whether that approach continues to hold as the company pursues further international deals will depend in part on how successfully it manages the logistical and regulatory demands of operating across increasingly distant markets.

For now, Mastaplex's focus remains on translating its Dunedin-based research into practical tools for farmers thousands of miles away, betting that the underlying problem of mastitis, and the demand for better ways to detect it early, is universal enough to sustain its expansion plans.

‍